|
|
|
|
Adventrx Slides on FDA Letter; Manufacturer Switch the Cause?
The FDA has dealt Adventrx Pharmaceuticals Inc.a blow that could delay by up to seven months the review of the San Diego-based firm's application for its non-small-cell lung cancer compound ANX-530. In a refuse-to-file letter, which the company received...
|
|
|
Adventrx Slides on FDA Letter; Manufacturer Switch the Cause?
The FDA has dealt Adventrx Pharmaceuticals Inc.a blow that could delay by up to seven months the review of the San Diego-based firm's application for its non-small-cell lung cancer compound ANX-530. In a refuse-to-file letter, which the company received...
|
|
|
FDA Refuses to Accept Adventrx Pharmas New Drug Application
Adventrx Pharmaceuticals, the San Diego biotech that sprang back to life in January with a new drug application, says in a statement today that it has received a refuse to file letter from the FDAwhich basically means its back to the drawing board.Adventrx...
|
|
|
FDA Refuses to Accept Adventrx Pharmas New Drug Application
FDA , New Drug Application , cancer Bruce V.Bigelow wrote: Adventrx Pharmaceuticals, the San Diego biotech that sprang back to life in January with a new drug application, says in a statement today that it has received a refuse to file letter from the...
|
|
|
FDA Issues Refuse To File Letter To Adventrx Pharma On ANX-530 NDA - Update
3/1/2010 2:03 AM ET RELATED NEWS Trade ANX now with TOP MARKET NEWS (RTTNews) - Adventrx Pharmaceuticals, Inc.(ANX: News ) Monday said it received a refuse to file letter from the U.S. Food and Drug Administration regarding its New Drug Application, or NDA...
|
|
|
Advantrx Pharma seeks US FDA approval for vinorelbine
Advantrx Pharmaceuticals, Inc has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its product candidate ANX-530 (vinorelbine injectable emulsion).'I congratulate our development team for achieving this important...
|
|
|
ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application
{'s' : 'anx','k' : 'c10,l10,p20,t10','o' : '','j' : ''} SAN DIEGO, Jan.4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration...
|
|
|
ADVENTRX Pharmaceuticals Submits ANX-530 New Drug Application
See more news releases in: Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals SAN DIEGO, Jan.4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) announced today that it has submitted a New Drug Application ...
|
|
|
Ichan's Adventrx Pharmaceuticals Ready To Run
2009-12-2311:02ET - News Release After an anticipated pullback yesterday, traders are looking for another run up by Adventrx Pharmaceuticals Inc.(Amex:ANX). Within days, the company is expected to submit its New Drug Application for ANX-530, which is a...
|
